Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Besides the presence of amyloid beta (Aβ) plaques and neurofibrillary tangles, neurogenesis and synaptic plasticity are markedly impaired in Alzheimer's disease (AD) possibly contributing to cognitive impairment. In this context, neurotrophic factors serve as a promising therapeutic approach via utilization of regenerative capacity of brain to shift the balance from neurodegeneration to neural regeneration. However, besides more conventional "bystander" effect, to what extent can neurotrophic compounds affect underlying AD pathology remains questionable. Here we investigated the effect of chronic oral treatment with a ciliary neurotrophic factor (CNTF) derived peptidergic compound, P021 (Ac-DGGL(A)G-NH2), on disease pathology both at moderate and severe stages in a transgenic mouse model of AD. 3xTg-AD and wild type female mice were treated for 12months with P021 or vehicle diet starting at 9-10months of age. A significant reduction in abnormal hyperphosphorylation and accumulation of tau at known major AD neurofibrillary pathology associated sites was observed. The effect of P021 on Aβ pathology was limited to a significant decrease in soluble Aβ levels and a trend towards reduction in Aβ plaque load in CA1 region of hippocampus, consistent with reduction in Aβ generation and not clearance. This disease modifying effect was probably via increased brain derived neurotrophic factor (BDNF) expression mediated decrease in glycogen synthase kinase-3-β (GSK3β) activity we found in P021 treated 3xTg-AD mice. P021 treatment also rescued deficits in cognition, neurogenesis, and synaptic plasticity in 3xTg-AD mice. These findings demonstrate the potential of the neurotrophic peptide mimetic as a disease modifying therapy for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“AD has been characterized as a synaptic failure (Arendt, 2009; Selkoe, 2002).”
Malenka, R. C., & Bear, M. F. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.012 · Cited by 3,968
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Self-citationChronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Self-citationNagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 3×
“, 2009) and BDNF gene delivery in APP + PS1 mice (Nagahara et al., 2009), both treatments that rescued synaptic plasticity deficit and cognitive impairment, failed to show any disease-modifying effect.”
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017 · cited 2×
“The extent of synaptic loss is even more profound in the hippocampus where it amounts to 44–55% (Davies et al., 1987; Scheff et al., 2006, 2007).”
Synaptic AMPA receptor plasticity and behavior
Kessels, H. W., & Malinow, R. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.015 · Cited by 993 · cited 2×
“…a general consensus has emerged that LTP is mediated by synaptic insertion of GluR1 subunit containing AMPA receptors (Anggono and Huganir, 2012; Kessels and Malinow, 2009) as LTP and short-term working memory are impaired in GluR1 knockout mice (Zamanillo et al., 1999; for review, Sanderson et…”
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 4×
“In AD brain, neuroinflammation, as evident by astrogliosis and microglial activation, is well documented (Wyss-Coray and Rogers, 2012).”
Influential
Cited by
Tau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
Self-citationTargeting the Synapse in Alzheimer’s Disease
Jackson, J., Jambrina, E., Li, J., Marston, H., Menzies, F., Phillips, K., & Gilmour, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00735 · Cited by 215
“Finally, administration of truncated ciliary neurotrophic factor in amyloid and tau mouse models restored synaptic loss and concomitant behavioral deficits (Kazim et al., 2014), however, treating outside the hypothetical compensation window may also yield similar effects (Bolognin et al.”
BackgroundRodent models for Alzheimer’s disease drug discovery
Puzzo, D., Gulisano, W., Palmeri, A., & Arancio, O. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1041913 · Cited by 222
“LTP and spatial memory impairment [50-53] were also evident.”
BackgroundKazim, S. F., Chuang, S.-C., Zhao, W., Wong, R. K. S., Bianchi, R., & Iqbal, K. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00071 · Cited by 109
“0 (Media Cybernetics, Silver Spring, MD, USA), as described previously (Kazim et al., 2014).”
MethodInfluentialSelf-citationDai, C.-L., Hu, W., Tung, Y. C., Liu, F., Gong, C.-X., & Iqbal, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0341-7 · Cited by 99
Self-citationSharma, A., Kazim, S. F., Larson, C. S., Ramakrishnan, A., Gray, J. D., McEwen, B. S., Rosenberg, P. A., Shen, L., & Pereira, A. C. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903566116 · Cited by 92
Self-citationTau and Alzheimer's disease: Past, present and future
Iqbal, K. (2024) · Cytoskeleton · doi:10.1002/cm.21822 · Cited by 35
Self-citationColin, J., Thomas, M. H., Gregory-Pauron, L., Pinçon, A., Lanhers, M.-C., Corbier, C., Claudepierre, T., Yen, F. T., Oster, T., & Malaplate-Armand, C. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.02.015 · Cited by 14
Metadata
- Authors
- Kazim, S. F., Blanchard, J., Dai, C.-L., Tung, Y.-C., LaFerla, F. M., Iqbal, I.-G., & Iqbal, K.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 71
- Pages
- 110-130
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2050912908
- Cited by
- 83
- References
- 37
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.